MX2023011821A - Composicion farmaceutica y metodo para tratamiento de los trastornos convulsivos. - Google Patents

Composicion farmaceutica y metodo para tratamiento de los trastornos convulsivos.

Info

Publication number
MX2023011821A
MX2023011821A MX2023011821A MX2023011821A MX2023011821A MX 2023011821 A MX2023011821 A MX 2023011821A MX 2023011821 A MX2023011821 A MX 2023011821A MX 2023011821 A MX2023011821 A MX 2023011821A MX 2023011821 A MX2023011821 A MX 2023011821A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
seizure disorders
treating seizure
treating
treatment
Prior art date
Application number
MX2023011821A
Other languages
English (en)
Spanish (es)
Inventor
Marina Borovinskaya
Nisarg Modi
Tamanna Lather
Fotios M Plakogiannis
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/225,654 external-priority patent/US12016829B2/en
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of MX2023011821A publication Critical patent/MX2023011821A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023011821A 2021-04-08 2022-04-07 Composicion farmaceutica y metodo para tratamiento de los trastornos convulsivos. MX2023011821A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/225,654 US12016829B2 (en) 2019-10-11 2021-04-08 Pharmaceutical composition and method for treating seizure disorders
PCT/IB2022/053271 WO2022215030A1 (en) 2021-04-08 2022-04-07 Pharmaceutical composition and method for treating seizure disorders

Publications (1)

Publication Number Publication Date
MX2023011821A true MX2023011821A (es) 2023-10-13

Family

ID=83546168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011821A MX2023011821A (es) 2021-04-08 2022-04-07 Composicion farmaceutica y metodo para tratamiento de los trastornos convulsivos.

Country Status (7)

Country Link
EP (1) EP4319730A4 (enExample)
JP (1) JP2024514843A (enExample)
CN (1) CN117479930A (enExample)
AU (1) AU2022255944A1 (enExample)
CA (1) CA3213953A1 (enExample)
MX (1) MX2023011821A (enExample)
WO (1) WO2022215030A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127033A1 (en) * 2009-04-28 2010-11-04 Alltranz Inc. Formulations of cannabidiol and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
US9962340B2 (en) * 2015-06-09 2018-05-08 Life Tech Global, Llc Device and method for the transdermal delivery of cannabidiol
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN109498606A (zh) * 2017-09-15 2019-03-22 汉义生物科技(北京)有限公司 一种含有大麻二酚和/或次大麻二酚的组合物及其在治疗痛经中的应用
JOP20200045A1 (ar) * 2017-09-19 2020-02-27 Zynerba Pharmaceuticals Inc كانابيدْيُول تخليقي يتم تناوله عبر الأدمة لعلاج الصرع البؤري لدى البالغين
US10821084B2 (en) * 2018-01-31 2020-11-03 Remy Biosciences, Inc. Dihydromyricetin compositions
WO2021055499A1 (en) * 2019-09-17 2021-03-25 Zynerba Pharmaceuticals, Inc. Treatment of behavioral impairment in developmental and epileptic encephalopathy
US12186280B2 (en) * 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
JP2022551730A (ja) * 2019-10-14 2022-12-13 パイク セラピューティクス,インコーポレイテッド カンナビジオールの経皮送達
AU2021392090A1 (en) * 2020-12-03 2023-07-06 Harmony Biosciences Management, Inc. Cannabidiol for the treatment of refractory seizures

Also Published As

Publication number Publication date
EP4319730A1 (en) 2024-02-14
AU2022255944A1 (en) 2023-10-12
CN117479930A (zh) 2024-01-30
EP4319730A4 (en) 2025-03-12
CA3213953A1 (en) 2022-10-13
WO2022215030A1 (en) 2022-10-13
JP2024514843A (ja) 2024-04-03

Similar Documents

Publication Publication Date Title
MX2022004257A (es) Composicion farmaceutica y metodo para tratamiento de los trastornos convulsionales.
KR101882400B1 (ko) 셀룰라이트 개선성분 및 항산화 유효성분, 부종감소 및 통증완화 성분을 함유한 다이어트 주사용 조성물
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MX2022010483A (es) Metodos de tratamiento del complejo de esclerosis tuberosa con cannabidiol y everolimus.
PY2181479A (es) Uso de cannabinoides en el tratamiento de la epilepsia
MX2023013338A (es) Derivados de cannabidiol-c4 para el tratamiento de epilepsia.
MX2021000987A (es) Metodo para tratar la epilepsia.
MX2024008086A (es) Composiciones y metodos para tratar la epilepsia
JOP20220061A1 (ar) علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي
CL2022003507A1 (es) Composición y método para tratar el dolor crónico
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
MX2023009600A (es) Análogos de la oxa-ibogaína para el tratamiento de trastornos por consumo de sustancias.
WO2022159501A3 (en) Methods and compositions for treating neurodegenerative diseases
EA202192928A1 (ru) Терапевтическое лекарственное средство для лечения дискинезии
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
MX2026000101A (es) Formulacion de ruxolitinib para la reduccion de comezon en dermatitis atopica
WO2012104241A1 (de) Kombinationen von aromatase inhibitoren und antioxidanzien
BR112022024461A2 (pt) Composição oftálmica tópica e método para o tratamento de um distúrbio oftálmico
AR124639A1 (es) Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión
BR112022025901A2 (pt) Composições e métodos para tratar transtorno obsessivo-compulsivo
JOP20230169A1 (ar) علاج انقطاع النفس أثناء النوم باستخدام cbd
MX2024008085A (es) Composiciones y metodos para tratar la epilepsia
RU2477628C2 (ru) Способ лечения язвенных кератитов
MX2022007109A (es) Composiciones para el cuidado personal y metodos para estas.
Sharma et al. Exploring Nature’s Pharmacy: Herbal Interventions for Gastric Ulcers in Diabetic Conditions–A Mechanistic Review